Consensus Repligen Corporation

Equities

RGEN

US7599161095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
141.2 ^USD	-3.12%		-6.07%	-21.45%

Jun. 06	Transcript : Repligen Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 11:30 AM
Jun. 05	Transcript : Repligen Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 12:00 PM

Evolution of the average Target Price on Repligen Corporation

Price target over the last 5 years

History of analyst recommendation changes

cc00b742a84dc41be25eef0da3b7174c.H2OZM540p8hEfYEQkeNeoRGRN_cVNgVkUs2RYk9-8PE.SFDzStkCwoZ0T-lo6bsa7kX0Z8VUWU9TK6vwOzs0qMBZMPp_7gLW-mk66g~5e39be2261dcaf30274b0ef2efab00ce

Analyst Recommendations on Repligen Corporation

Repligen Insider Sold Shares Worth $3,377,283, According to a Recent SEC Filing	May. 22	MT
UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating	May. 02	MT
RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	Apr. 08	MT
UBS Adjusts Repligen Price Target to $225 From $211, Maintains Buy Rating	Feb. 22	MT
Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating	Feb. 22	MT
RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating	Feb. 22	MT
Stocks Decline Pre-Bell as Fed Outlook, Rates Weigh; Asia Mixed, Europe Mostly Up	Feb. 21	MT
Deutsche Bank Adjusts Repligen Price Target to $175 From $150, Maintains Hold Rating	Dec. 18	MT
UBS Adjusts Repligen Price Target to $211 From $170, Maintains Buy Rating	Dec. 15	MT
Benchmark Downgrades Repligen to Hold From Buy	Dec. 04	MT
Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating	Nov. 07	MT
CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating	Nov. 03	MT
RBC Trims Price Target on Repligen to $837 From $847, Keeps Sector Perform Rating	Nov. 03	MT
UBS Adjusts Repligen Price Target to $170 From $210, Maintains Buy Rating	Nov. 01	MT
KeyBanc Lowers Price Target on Repligen to $210 From $240, Maintains Overweight Rating	Nov. 01	MT
Craig Hallum Cuts Repligen Price Target to $175 From $200, Maintains Buy Rating	Nov. 01	MT
RBC Cuts Price Target on Repligen to $200 From $207, Keeps Outperform Rating	Nov. 01	MT
JPMorgan Cuts Repligen Price Target to $180 From $200, Maintains Overweight Rating	23-10-17	MT
UBS Adjusts Repligen Price Target to $210 From $199, Maintains Buy Rating	23-08-03	MT
Stephens Adjusts Price Target on Repligen to $200 From $180, Maintains Overweight Rating	23-08-03	MT
RBC Boosts Price Target on Repligen to $195 From $157, Keeps Outperform Rating	23-08-03	MT
Wells Fargo Initiates Coverage on Repligen With Overweight Rating, $185 Price Target	23-07-20	MT
RBC Upgrades Repligen to Outperform From Sector Perform, Price Target is $157	23-07-06	MT
UBS Adjusts Repligen Price Target to $199 From $210, Maintains Buy Rating	23-05-15	MT
Powell's mixed signals and Pacwest weigh on US indices	23-05-04

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

141.2 USD

Average target price

203.7 USD

Spread / Average Target

+44.24%

High Price Target

225 USD

Spread / Highest target

+59.31%

Low Price Target

165 USD

Spread / Lowest Target

+16.83%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Repligen Corporation

UBS
RBC Capital Markets
Deutsche Bank Securities
Benchmark Company
KeyBanc Capital Markets
Craig-Hallum
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Stifel Nicolaus
SVB Securities LLC
SVB Leerink
Exane BNP Paribas
William O'Neil & Co
HC Wainwright

Ratings for Repligen Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar